The latest update is out from Ibio (IBIO).
iBio, Inc. has updated its employment agreement with CEO and Chief Scientific Officer Martin Brenner, offering him a base salary of $522,365 and a raised bonus target of 50% for fiscal year 2025. Brenner’s employment is at-will but includes comprehensive termination benefits, such as a year’s base salary and potential COBRA coverage following his departure. In case of a company sale, these benefits extend to eighteen months’ salary and health insurance, along with accelerated equity award vesting. Brenner is also bound by non-solicitation clauses and must assign any inventions made during his tenure to the company.
For detailed information about IBIO stock, go to TipRanks’ Stock Analysis page.
